Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

Moderna plans to prioritize new product approvals and oncology investments, as political concerns over Robert F. Kennedy Jr.'s HHS nomination weigh on vaccine stocks.

Shares in biotech firm Moderna (NASDAQ:MRNA) rose more than 4% Monday after HSBC raised its rating on the stock from Hold to ...

CNBC's Jim Cramer reports on the latest news regarding Moderna. This Insane Timelapse From Hubble Will Change Your ...

Piper Sandler lowered the firm’s price target on Moderna (MRNA) to $69 from $115 and keeps an Overweight rating on the shares. The firm notes ...

HSBC upgraded Moderna (MRNA) to Hold from Reduce with a $58 price target Don't Miss our Black Friday Offers:Discover the latest stocks ...

Moderna’s ( NASDAQ: MRNA) steep fall on Friday after President-elect Donald Trump selected vaccine critic Robert F. Kennedy Jr. to head the U.S. Department of Health and Human Services makes a good ...

Pfizer's stock dropped 4.3 percent while Moderna's fell 3.1 percent and Novavax saw a 2.8 percent dip in its stock Friday ...

( NewsNation) — Shares in some pharmaceutical and biotechnology companies, including those that manufacture vaccines, fell ...

The standout company among those yet to report is Nvidia Corp. (NVDA), which is scheduled to announce quarterly results on Wednesday.

Kennedy Jr., a prominent anti-vaccine activist, to be his Secretary of Health and Human Services. Moderna tumbled 6.2%, and Pfizer fell 4.8% amid concerns about a possible hit to profits. Kennedy ...

Pharmaceutical industry representatives in Washington are scrambling to measure the damage Robert F. Kennedy Jr. might inflict on the FDA.